- Home
- IBCP vs NTLA Comparison
IBCP vs NTLA Comparison
Compare IBCP & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBCP
- NTLA
- Stock Information
- Founded
- IBCP 1864
- NTLA 2014
- Country
- IBCP United States
- NTLA United States
- Employees
- IBCP N/A
- NTLA N/A
- Industry
- IBCP Major Banks
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- IBCP Finance
- NTLA Health Care
- Exchange
- IBCP Nasdaq
- NTLA Nasdaq
- Market Cap
- IBCP 630.0M
- NTLA 710.1M
- IPO Year
- IBCP N/A
- NTLA 2016
- Fundamental
- Price
- IBCP $31.64
- NTLA $8.12
- Analyst Decision
- IBCP Hold
- NTLA Buy
- Analyst Count
- IBCP 3
- NTLA 19
- Target Price
- IBCP $36.67
- NTLA $38.26
- AVG Volume (30 Days)
- IBCP 106.0K
- NTLA 3.1M
- Earning Date
- IBCP 04-24-2025
- NTLA 05-08-2025
- Dividend Yield
- IBCP 3.28%
- NTLA N/A
- EPS Growth
- IBCP 6.78
- NTLA N/A
- EPS
- IBCP 3.14
- NTLA N/A
- Revenue
- IBCP $219,516,000.00
- NTLA $45,569,000.00
- Revenue This Year
- IBCP N/A
- NTLA N/A
- Revenue Next Year
- IBCP $6.51
- NTLA N/A
- P/E Ratio
- IBCP $10.10
- NTLA N/A
- Revenue Growth
- IBCP 6.57
- NTLA N/A
- 52 Week Low
- IBCP $22.53
- NTLA $5.90
- 52 Week High
- IBCP $40.32
- NTLA $28.18
- Technical
- Relative Strength Index (RSI)
- IBCP 57.45
- NTLA 50.39
- Support Level
- IBCP $30.76
- NTLA $7.21
- Resistance Level
- IBCP $32.05
- NTLA $9.27
- Average True Range (ATR)
- IBCP 0.87
- NTLA 0.61
- MACD
- IBCP 0.18
- NTLA 0.02
- Stochastic Oscillator
- IBCP 81.28
- NTLA 44.20
About IBCP Independent Bank Corporation
Independent Bank Corp (Ionia MI) operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.